期刊文献+

手术切除小细胞肺癌P53蛋白表达及意义 被引量:1

Expression of P53 Protein in Resected Small Cell Lung Cancer and Its Significance
下载PDF
导出
摘要 目的研究手术切除小细胞肺癌(SCLC)P53蛋白表达,探讨其临床意义。方法取根治术后>5年,术前未放疗、化疗标本32例;石蜡切片,ABC染色。结果P53蛋白表达总阳性率81.3%(26/32);P53蛋白表达与性别、吸烟、PTNM分期、淋巴结转移、原发病灶大小相关不显著(P>0.05)。术后2年内死亡组P53阳性率100%(14/14),>5年死亡组42.9%(3/7)(P<0.01)。前者死亡风险比后者高2倍。脑转移者P53阳性率85.7%(6/7)。结论P53蛋白在SCLC中有高表达,它与SCLC术后的近期死亡及脑转移有关。 Objective To study the expression of P53 protein in resected pathologically small cell lung cancer (SCLC) and to explore its clinical significance. Methods Thirty two samples were taken according to standard over 5 years after radical surgical operation and without radiotherapy and chemotherapy before the operation, with paraffin embedded specimens and immunohistochemical ABC methods. Results The total positive expression rate of P53 protein was found to be 81.3%(26/32). The correlation between the expression rate of P53 protein and sex, smoking, PTNM stage, lymph node metastasis and primary cancer focus had no statistics significance ( P>0.05) .With postoperative patients both survival less than 2 years and more than 5 years, the frequency of P53 expression reached 100% (14/14) and 42.9% (3/7) ( P<0.01) respectively, but the relative risk of death was high about 2 times for former to later. The frequency showed 85.7% (6/7) in the patients with the brain metastasis. Conclusion There was obvious overexpression of P53 protein in SCLC. It is related to the recent death and brain metastases after surgical treatment. P53 protein is a good index to estimate postoperative prognosis of SCLC.
出处 《中国胸心血管外科临床杂志》 CAS 1998年第4期220-222,共3页 Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
基金 国家八五攻关及分子肿瘤学国家重点实验室课题
关键词 小细胞肺癌 P53蛋白 免疫组织化学 外科手术 Small cell lung cancer P53 protein Immunohistochemistry
  • 相关文献

同被引文献12

  • 1吴阶平 裘法祖 吴蔚然等 见:石美鑫 主编.黄家驷外科学[A].见:石美鑫,主编.肺肿瘤.第六版[C].北京:人民卫生出版社,2000.1466.
  • 2El- Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a protein mediatar ,of p53 tumar suppressor. Cell, 1993:75:817- 825.
  • 3LU ML, Wikmask F, Orntoft TF, et al. Impart of Alterations Affecting the p53 pathway in Bladder Cancer on Clinical Out come, Assesmd by Conventional and Array- based Methods. Clinical Cancer Research,2002;8(1) : 171-173.
  • 4Quinlain DC, Daidson AG,Summers CL, et al. Accummulation p53 protein correlates with a Poor prognosis in lung cancer. Cancer, 1992;66.735-738.
  • 5Lee JS, Yoon A, Kalapurakal SK, et al. Expression of p53 oncoprtein in non small cell lung cancer: a favorable prognoses factor. J Clin Oncol, 1984;38:331 - 336.
  • 6Ebina M, Steinberg SM, Mul shine JL, et al. Relationship of p53 over expression and up regulation of proliferating cell nuclear antigen the with the clinical course of noon- small lung cancer. Cancer Res, 1994;64:2496-2503.
  • 7Miller CW, Simonk, Anto A, et al. p53 mutations in human lung tumors, Cancer Res, 1992;52(8):1695.
  • 8Levine AJ. The road to the discovery of the p53 protein. Int J Cancer,1994;56(6):775.
  • 9Gomyo Y, Ikeda M, Osaki M, et al. Expression of p21(WAF1/CIP1/sdil), hut not p63 protein is a factor in the survival of pastients with advanced gastric carcinoma. Cancer, 1997;79:2067-2072.
  • 10Xiangming C, Hokita S, Natsugoe S, et al. p21 expression is a prognostic factor in patients with p53- negative hastric cancer. Cancer Lett, 2000; 148:181 - 188.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部